Sign inJoin waitlistJoin the waitlist

Matthew Zibelman

Director, Genitourinary Clinical Research · Temple University Hospital

Credentials: · · · · ·

History

Genitourinary Clinical Research · Temple University Hospital
Present
Temple University Hospital
Present
Temple University Hospital
Present

Hematology and Medical Oncology
Temple University Hospital
2010–2013
Internal Medicine
2007–2010
Temple University School of Medicine
2003–2007

Research

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised,…
The Lancet · 2022 · 210 citations
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024 · 168 citations
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Journal for ImmunoTherapy of Cancer · 2018 · 129 citations

Elizabeth Plimack
42 papers
Daniel Geynisman
38 papers
Pooja Ghatalia
26 papers · 9 as a fellow
Alexander Kutikov
16 papers
Robert Uzzo
16 papers
Fern Anari
14 papers · 3 as a fellow
Marc Smaldone
11 papers · 3 as a resident
Rosalia Viterbo
9 papers
David Chen
8 papers
RG
Richard Greenberg
8 papers
BM
Benjamin Miron
7 papers
Paul O'Neill
6 papers · 2 as a resident

Clinical trials

Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
Principal investigator · Recruiting · Phase 2
Fox Chase Cancer Center
2026–2028
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Principal investigator · Recruiting · Phase 2
Fox Chase Cancer Center
2022–2027
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Principal investigator · Completed · Phase 1
Fox Chase Cancer Center
2015–2019
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Site PI · Recruiting · Phase 2, Phase 3
Novartis Pharmaceuticals
2025–2033